Oncology_Logotype-site-1Oncology_Logotype-site-1Oncology_Logotype-site-1Oncology_Logotype-site-1
  • Main
  • Сlinical Trials
    • Completed phase I/IIa clinical trial
    • Case studies
    • Ex-US Clinical Trials
    • US clinical trials
  • Dogs & Cats
    • Comparative Medicine and Veterinary Research
  • Elenagen
    • Elenagen is a Plasmid (Circular DNA) Encoding Gene P62/SQSTM1
    • Elenagen Reduces/Reverts Tumor Grade
    • Elenagen Changes Tumor Microenvironment
    • Elenagen Downregulates Chronic Inflammation
    • Elenagen Enhances Anti-Tumoral Immune Response
  • IP
  • Publications
  • Investors
    • One-pager
    • Slide presentation
  • Team
    • Management Team
    • Scientific Advisory Board
    • Board of Directors
    • Careers
  • News
    • Company news
    • In the news
  • Legal
University of Camerino Signs Strategic Partnership with CureLab Veterinary to Revolutionize Cancer Treatment for Companion Animals
April 22, 2022
ESMO 2022: Interim Results for Treatment of Platinum-Resistant Ovarian Cancer with p62 Plasmid DNA Show Statistically Significant Changes in Progression-Free Survival
September 10, 2022
May 3, 2022

CureLab Oncology Secures Patent Protection for P62 Plasmid Therapeutic in South Korea

Patent registration in South Korea opens door to commercial agreements in an enormous market with high economic potential for CureLab
South Korea-1

BOSTON – May 3, 2022: CureLab Oncology , a clinical-stage biotech company, has been granted a patent in South Korea for the treatment of non-cancerous diseases of chronic inflammation with its lead product, the DNA plasmid coding p62/SQSTM1 gene (p62). Chronic inflammation is an underlying condition that manifests itself in different organs and tissues as a multitude of diseases.

CureLab’s research has been focused on a new strategy for treatment of various diseases that involve chronic inflammation in their pathogenesis. CureLab’s lead product, Elenagen™, reduces chronic inflammation. In its ongoing cancer clinical studies, CureLab has observed a desirable safety profile and preliminary evidence of clinical benefits of Elenagen for cancer patients.

Based on this research, the company is planning to initiate clinical trials testing its lead product as an anti-cancer agent against psoriasis, osteoporosis, metabolic syndrome/type 2 diabetes, cardiovascular, CNS, lupus, and psychiatric diseases.

With a population of 51 million, South Korea is the world’s tenth-largest economy. South Koreans have access to excellent universal healthcare, access to which is ranked first in the OECD. The life expectancy of South Koreans is currently over 82 years and rising. Taken together, these factors make this new patent of high economic potential for CureLab Oncology

About CureLab Oncology

CureLab Oncology Inc. is a pre-IPO, clinical-stage immuno-oncology biotech company headquartered near Boston, Massachusetts. CureLab is dedicated to advancing new and safer therapeutics for solid tumors and other oncology and inflammatory indications. To learn more, visit curelab.com.

Media contact:

Tim Cox, ZingPR, tim@zingpr.com

Share

Related posts

November 5, 2022

Biotech Internship Opportunity! FDA/USDA liaison


Read more

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Corporate Mission

CureLab Oncology is a biotechnology company that is developing new anti-cancer biologics.
CureLab Oncology is committed to creating a family of revolutionary
therapies for oncology patients in order to help prolong their lives.

Our Lead Product

Our lead product, Elenagen, is a plasmid (supercoiled circular DNA) encoding gene p62/SQSTM1. Elenagen reverses tumor grade, changes tumor microenvironment, enhances the anti-cancer effects of other therapies (e.g. chemotherapy), mitigates chronic inflammation, and stimulates an immune attack on the tumor.

Clinical Trials

  • The CureLab Oncology team has completed its international Phase I/IIa Clinical Trials of Elenagen.
  • The vaccine demonstrated a high degree of safety as well as clinical benefits in a number of patients.
  • We are now preparing Phase II Clinical Trials within the US.

Contact us

E-mail:

info@curelab.com,

Call us:

1-609-841-1201

177 HUNTINGTON
AVE FL 17
BOSTON MA 02115-3156
© 2020 CureLab Oncology.